EDESA BIOTECH, INC. Research and Development Expense
EDESA BIOTECH, INC. (EDSA) reported Research and Development Expense of $3.96 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- EDESA BIOTECH, INC. research and development expense for the quarter ending 2026-06-30 was $3.96M, a 321.47% increase year-over-year.
- EDESA BIOTECH, INC. research and development expense for the quarter ending 2026-03-31 was $2.77M, a 471.35% increase year-over-year.
- EDESA BIOTECH, INC. research and development expense for the quarter ending 2025-12-31 was $1.12M, a 10.29% increase year-over-year.
- EDESA BIOTECH, INC. research and development expense for the quarter ending 2025-09-30 was $1.23M, a 1079.92% increase year-over-year.
- EDESA BIOTECH, INC. research and development expense for fiscal 2025 was $3.67M, a 27.30% increase from fiscal 2024.
- EDESA BIOTECH, INC. research and development expense for fiscal 2024 was $2.88M, a 39.89% decline from fiscal 2023.
- EDESA BIOTECH, INC. research and development expense for fiscal 2023 was $4.79M, a 64.05% decline from fiscal 2022.
- EDESA BIOTECH, INC. research and development expense for fiscal 2022 was $13.34M, a 25.70% decline from fiscal 2021.
| Period end | Research and Development Expense 1 month | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.96M 10-Q · filed 2026-08-13 | $6.72M derived: sum of 2 quarters · filed 2026-08-13 | $7.85M 10-Q · filed 2026-08-13 | $9.08M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2026-03-31 | $2.77M 10-Q · filed 2026-05-14 | $3.89M 10-Q · filed 2026-05-14 | $5.12M derived: sum of 3 quarters · filed 2026-05-14 | $6.06M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-12-31 | $1.12M 10-Q · filed 2026-02-13 | $2.35M derived: sum of 2 quarters · filed 2026-02-13 | $3.29M derived: sum of 3 quarters · filed 2026-08-13 | $3.77M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-09-30 | $1.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $2.16M derived: sum of 2 quarters · filed 2026-08-13 | $2.65M derived: sum of 3 quarters · filed 2026-08-13 | $3.67M 10-K · filed 2025-12-12 | |||
| 2025-06-30 | $939.07K 10-Q · filed 2026-08-13 | $1.42M derived: sum of 2 quarters · filed 2026-08-13 | $2.44M 10-Q · filed 2026-08-13 | $2.55M derived: sum of 4 quarters · filed 2026-08-13 | |||
| 2025-03-31 | $484.31K 10-Q · filed 2026-05-14 | $1.50M 10-Q · filed 2026-05-14 | $1.61M derived: sum of 3 quarters · filed 2026-05-14 | $2.51M derived: sum of 4 quarters · filed 2026-05-14 | |||
| 2024-12-31 | $1.02M 10-Q · filed 2026-02-13 | $1.12M derived: sum of 2 quarters · filed 2026-02-13 | $2.02M derived: sum of 3 quarters · filed 2026-02-13 | $3.20M derived: sum of 4 quarters · filed 2026-02-13 | |||
| 2024-09-30 | $103.87K derived: 10-K 12 month − 10-Q 9 month · filed 2025-12-12 | $1.00M derived: sum of 2 quarters · filed 2025-12-12 | $2.18M derived: sum of 3 quarters · filed 2025-12-12 | $2.88M 10-K · filed 2025-12-12 | |||
| 2024-06-30 | $897.30K 10-Q · filed 2025-08-08 | $2.07M derived: sum of 2 quarters · filed 2025-08-08 | $2.78M 10-Q · filed 2025-08-08 | $3.73M derived: sum of 4 quarters · filed 2025-08-08 | |||
| 2024-03-31 | $1.18M 10-Q · filed 2025-05-14 | $1.88M 10-Q · filed 2025-05-14 | $2.83M derived: sum of 3 quarters · filed 2025-05-14 | $3.86M derived: sum of 4 quarters · filed 2025-05-14 | |||
| 2023-12-31 | $704.46K 10-Q · filed 2025-02-14 | $1.66M derived: sum of 2 quarters · filed 2025-02-14 | $2.68M derived: sum of 3 quarters · filed 2025-02-14 | $4.14M derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2023-09-30 | $953.40K derived: 10-K 12 month − 10-Q 9 month · filed 2024-12-13 | $1.98M derived: sum of 2 quarters · filed 2024-12-13 | $3.44M derived: sum of 3 quarters · filed 2024-12-13 | $4.79M 10-K · filed 2024-12-13 | |||
| 2023-06-30 | $1.03M 10-Q · filed 2024-08-09 | $2.48M derived: sum of 2 quarters · filed 2024-08-09 | $3.84M 10-Q · filed 2024-08-09 | $5.64M derived: sum of 4 quarters · filed 2024-08-09 | |||
| 2023-03-31 | $1.46M 10-Q · filed 2024-05-10 | $2.82M 10-Q · filed 2024-05-10 | $4.61M derived: sum of 3 quarters · filed 2024-05-10 | $9.16M derived: sum of 4 quarters · filed 2024-05-10 | |||
| 2022-12-31 | $1.36M 10-Q · filed 2024-02-09 | $3.15M derived: sum of 2 quarters · filed 2024-02-09 | $7.70M derived: sum of 3 quarters · filed 2024-02-09 | $10.74M derived: sum of 4 quarters · filed 2024-02-09 | |||
| 2022-09-30 | $1.79M derived: 10-K 12 month − 10-Q 9 month · filed 2023-12-15 | $6.34M derived: sum of 2 quarters · filed 2023-12-15 | $9.38M derived: sum of 3 quarters · filed 2023-12-15 | $13.34M 10-K · filed 2023-12-15 | |||
| 2022-06-30 | $4.55M 10-Q · filed 2023-08-09 | $7.59M derived: sum of 2 quarters · filed 2023-08-09 | $11.54M 10-Q · filed 2023-08-09 | $15.67M derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2022-03-31 | $3.04M 10-Q · filed 2023-05-11 | $6.99M 10-Q · filed 2023-05-11 | $11.12M derived: sum of 3 quarters · filed 2023-05-11 | $15.59M derived: sum of 4 quarters · filed 2023-05-11 | |||
| 2021-12-31 | $3.95M 10-Q · filed 2023-02-10 | $8.08M derived: sum of 2 quarters · filed 2023-02-10 | $12.54M derived: sum of 3 quarters · filed 2023-02-10 | $20.52M derived: sum of 4 quarters · filed 2023-02-10 | |||
| 2021-09-30 | $4.13M derived: 10-K 12 month − 10-Q 9 month · filed 2022-12-16 | $8.59M derived: sum of 2 quarters · filed 2022-12-16 | $16.57M derived: sum of 3 quarters · filed 2022-12-16 | $17.95M 10-K · filed 2022-12-16 | |||
| 2021-06-30 | $4.46M 10-Q · filed 2022-08-12 | $12.44M derived: sum of 2 quarters · filed 2022-08-12 | $13.82M 10-Q · filed 2022-08-12 | $14.97M derived: sum of 4 quarters · filed 2022-08-12 | |||
| 2021-03-31 | $7.98M 10-Q · filed 2022-05-13 | $9.35M 10-Q · filed 2022-05-13 | $10.51M derived: sum of 3 quarters · filed 2022-05-13 | $11.65M derived: sum of 4 quarters · filed 2022-05-13 | |||
| 2020-12-31 | $1.38M 10-Q · filed 2022-02-14 | $2.53M derived: sum of 2 quarters · filed 2022-02-14 | $3.68M derived: sum of 3 quarters · filed 2022-02-14 | $4.18M derived: sum of 4 quarters · filed 2022-02-14 | |||
| 2020-09-30 | $1.15M derived: 10-K 12 month − 10-Q 9 month · filed 2021-12-28 | $2.30M derived: sum of 2 quarters · filed 2021-12-28 | $2.80M derived: sum of 3 quarters · filed 2021-12-28 | $3.33M 10-K · filed 2021-12-28 | |||
| 2020-06-30 | $1.14M 10-Q · filed 2021-08-13 | $1.65M derived: sum of 2 quarters · filed 2021-08-13 | $2.17M 10-Q · filed 2021-08-13 | $2.66M derived: sum of 4 quarters · filed 2021-08-13 | |||
| 2020-03-31 | $502.81K 10-Q · filed 2021-05-14 | $1.03M 10-Q · filed 2021-05-14 | $1.51M derived: sum of 3 quarters · filed 2021-05-14 | $2.02M derived: sum of 4 quarters · filed 2021-05-14 | |||
| 2019-12-31 | $528.00K 10-Q · filed 2021-02-16 | $1.01M derived: sum of 2 quarters · filed 2021-02-16 | $1.51M derived: sum of 3 quarters · filed 2021-02-16 | $1.62M derived: sum of 4 quarters · filed 2021-02-16 | |||
| 2019-09-30 | $481.80K derived: 10-K 9 month − 10-Q 6 month · filed 2020-12-07 | $984.72K derived: sum of 2 quarters · filed 2020-12-07 | $1.10M 10-K · filed 2020-12-07 | $1.35M derived: sum of 4 quarters · filed 2020-12-07 | |||
| 2019-06-30 | $502.93K 10-Q · filed 2020-08-12 | $614.63K 10-Q · filed 2019-08-14 | $872.02K 10-Q · filed 2020-08-12 | $1.37M derived: sum of 4 quarters · filed 2020-08-12 | |||
| 2019-03-31 | $111.70K 10-Q · filed 2020-05-15 | $375.73K 10-Q · filed 2019-05-08 | $369.09K 10-Q · filed 2020-05-15 | $846.02K 10-Q · filed 2019-05-08 | $866.41K derived: sum of 3 quarters · filed 2020-05-15 | $1.16M derived: sum of 4 quarters · filed 2020-05-15 | |
| 2018-12-31 | $257.39K 10-Q · filed 2020-02-13 | $470.28K 10-Q · filed 2019-02-05 | $754.71K derived: sum of 2 quarters · filed 2020-02-13 | $1.05M derived: sum of 3 quarters · filed 2020-02-13 | $1.08M 10-KT · filed 2019-12-12 | ||
| 2018-09-30 | $497.31K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-30 | $795.54K derived: sum of 2 quarters · filed 2019-08-14 | $1.29M derived: sum of 3 quarters · filed 2019-08-14 | $2.09M 10-K · filed 2018-11-30 | |||
| 2018-06-30 | $298.22K 10-Q · filed 2019-08-14 | $465.18K 10-Q · filed 2018-08-08 | $578.27K 10-Q · filed 2019-08-14 | $1.59M 10-Q · filed 2018-08-08 | $2.07M derived: sum of 4 quarters · filed 2019-08-14 | ||
| 2018-03-31 | $493.87K 10-Q · filed 2019-05-08 | $1.12M 10-Q · filed 2019-05-08 | $1.77M derived: sum of 3 quarters · filed 2019-05-08 | $2.31M derived: sum of 4 quarters · filed 2019-05-08 | |||
| 2017-12-31 | $631.03K 10-Q · filed 2019-02-05 | $1.28M derived: sum of 2 quarters · filed 2019-02-05 | $1.81M derived: sum of 3 quarters · filed 2019-02-05 | $2.14M derived: sum of 4 quarters · filed 2019-02-05 | |||
| 2017-09-30 | $647.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-11-30 | $1.18M derived: sum of 2 quarters · filed 2018-11-30 | $1.51M derived: sum of 3 quarters · filed 2018-11-30 | $1.97M 10-K · filed 2018-11-30 | |||
| 2017-06-30 | $536.17K 10-Q · filed 2018-08-08 | $865.54K derived: sum of 2 quarters · filed 2018-08-08 | $1.33M 10-Q · filed 2018-08-08 | $1.99M derived: sum of 4 quarters · filed 2018-08-08 | |||
| 2017-03-31 | $329.37K 10-Q · filed 2018-05-07 | $790.24K 10-Q · filed 2018-05-07 | $1.45M derived: sum of 3 quarters · filed 2018-05-07 | $1.92M derived: sum of 4 quarters · filed 2018-05-07 | |||
| 2016-12-31 | $460.87K 10-Q · filed 2018-02-07 | $1.12M derived: sum of 2 quarters · filed 2018-02-07 | $1.59M derived: sum of 3 quarters · filed 2018-02-07 | $1.90M derived: sum of 4 quarters · filed 2018-02-07 | |||
| 2016-09-30 | $661.44K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-01 | $1.13M derived: sum of 2 quarters · filed 2017-12-01 | $1.44M derived: sum of 3 quarters · filed 2017-12-01 | $1.73M 10-K · filed 2017-12-01 | |||
| 2016-06-30 | $470.10K 10-Q · filed 2017-08-09 | $779.16K derived: sum of 2 quarters · filed 2017-08-09 | $1.07M 10-Q · filed 2017-08-09 | $1.27M derived: sum of 4 quarters · filed 2017-12-01 | |||
| 2016-03-31 | $309.06K 10-Q · filed 2017-05-09 | $597.91K 10-Q · filed 2017-05-09 | $797.28K derived: sum of 3 quarters · filed 2017-12-01 | $927.00K derived: sum of 4 quarters · filed 2017-12-01 | |||
| 2015-12-31 | $288.85K 10-Q · filed 2017-02-06 | $488.22K derived: sum of 2 quarters · filed 2017-12-01 | $617.93K derived: sum of 3 quarters · filed 2017-12-01 | $899.52K derived: sum of 4 quarters · filed 2017-12-01 | |||
| 2015-09-30 | $199.37K derived: 10-K 12 month − 10-Q 9 month · filed 2017-12-01 | $329.08K derived: sum of 2 quarters · filed 2017-12-01 | $610.67K derived: sum of 3 quarters · filed 2017-12-01 | $1.03M 10-K · filed 2017-12-01 | |||
| 2015-06-30 | $129.71K 10-Q · filed 2016-08-09 | $411.29K derived: sum of 2 quarters · filed 2016-08-09 | $830.12K 10-Q · filed 2016-08-09 | ||||
| 2015-03-31 | $281.58K 10-Q · filed 2016-05-09 | $700.40K 10-Q · filed 2016-05-09 | |||||
| 2014-12-31 | $418.82K 10-Q · filed 2016-02-08 | ||||||
| 2014-09-30 | $178.28K 10-K · filed 2016-12-14 | ||||||
| 2014-08-31 | $2.46M 10-K · filed 2016-12-14 | ||||||
| 2014-06-30 | $543.23K 10-Q · filed 2015-08-10 | $1.28M derived: sum of 2 quarters · filed 2015-08-10 | $1.82M 10-Q · filed 2015-08-10 | ||||
| 2014-03-31 | $733.10K 10-Q · filed 2015-05-11 | $1.28M 10-Q · filed 2015-05-11 | |||||
| 2013-12-31 | $548.23K 10-Q · filed 2015-02-09 | ||||||
| 2013-09-30 | $203.37K 10-Q · filed 2015-02-09 | ||||||
| 2013-08-31 | $2.02M 10-K · filed 2015-12-14 | ||||||
| 2012-08-31 | $2.63M 10-K · filed 2014-11-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B | ||
| Seres Therapeutics, Inc. (MCRB) | United States | $0.036B | -3.45 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B |